Company: CWAN
Filing Date: 2025-01-13
Form Type: 425
Source: 0001104659-25-003010
Chunk: 13

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-01-13
Form: 425
Chunk 13
---
 proposed transaction; (d) the timing, receipt
and terms and conditions of any required governmental and regulatory approvals of the proposed transaction that could delay the consummation
of the proposed transaction or cause the parties to abandon the proposed transaction; (e) the possibility that the Company’s stockholders
may not approve the proposed transaction; (f) the ability of the Company or of Clearwater to timely and successfully achieve the anticipated
benefits of the proposed transaction; (g) the occurrence of any event, change or other circumstance or condition that could give rise
to the termination of the Merger Agreement; (h) the Company’s or Clearwater’s ability to implement its respective business
strategy; (i) significant transaction costs associated with the proposed transaction; (j) the possibility that the proposed transaction
may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (k) potential litigation relating
to the proposed transaction; (l) the risk that disruptions from the proposed transaction will harm the Company’s or Clearwater’s
business, including current plans and operations; (m) the ability of the Company or of Clearwater to retain and hire key personnel; (n)
potential adverse reactions or changes to business relationships of the Company or of Clearwater resulting from the announcement or completion
of the proposed transaction; (o) legislative, regulatory and economic developments affecting the Company’s or Clearwater’s
business; (p) general economic and market developments and conditions; (q) the legal, regulatory and tax regimes under which the Company
or Clearwater operates; (r) potential business uncertainty, including changes to existing business relationships, during the pendency
of the proposed transaction that could affect the Company’s or Clearwater’s financial performance; (s) the risk that any announcements
relating to the proposed transaction could have adverse effects on the market price of the Company’s Class A common stock or Clearwater’s
Class A common stock; (t) restrictions during the pendency of the proposed transaction that may impact the Company’s or Clearwater’s
ability to pursue certain business opportunities or strategic transactions; (u) Clearwater’s ability to successfully integrate the
Company’s operations into Clearwater’s business; (v) unpredictability and severity of catastrophic events, including, but
not limited to, acts of terrorism or outbreak of war or hostilities, and (w) the finalization and audit of Enfusion’s 2024 fiscal
year financial results which could potentially result in changes